HC Wainwright Weighs in on ProKidney FY2025 Earnings

ProKidney Corp. (NASDAQ:PROK) – Equities research analysts at HC Wainwright issued their FY2025 EPS estimates for shares of ProKidney in a research report issued to clients and investors on Tuesday, December 16th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.53) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for ProKidney’s Q4 2025 earnings at ($0.15) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.62) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at ($0.31) EPS.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ProKidney in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, ProKidney currently has an average rating of “Hold” and a consensus target price of $7.40.

ProKidney Stock Down 4.0%

Shares of NASDAQ PROK opened at $2.37 on Thursday. The company has a market cap of $712.97 million, a P/E ratio of -4.31 and a beta of 1.79. ProKidney has a 52 week low of $0.46 and a 52 week high of $7.13. The business has a 50-day simple moving average of $2.60 and a two-hundred day simple moving average of $2.38.

ProKidney (NASDAQ:PROK) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.04 million.

Insider Activity

In other news, Director Brian Jg Pereira sold 502,136 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $2.37, for a total transaction of $1,190,062.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 41.49% of the company’s stock.

Institutional Investors Weigh In On ProKidney

Several hedge funds have recently bought and sold shares of PROK. Charles Schwab Investment Management Inc. grew its stake in ProKidney by 8.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 825,647 shares of the company’s stock worth $723,000 after buying an additional 65,860 shares in the last quarter. Deutsche Bank AG grew its position in ProKidney by 49.4% in the first quarter. Deutsche Bank AG now owns 86,337 shares of the company’s stock worth $76,000 after acquiring an additional 28,546 shares in the last quarter. Nuveen LLC bought a new position in ProKidney in the first quarter valued at $233,000. AQR Capital Management LLC raised its position in ProKidney by 106.4% during the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after purchasing an additional 27,098 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in ProKidney during the second quarter valued at about $208,000. 51.59% of the stock is currently owned by institutional investors.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.